Insider Selling: Elanco Animal Health (NYSE:ELAN) Insider Sells $100,050.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) insider Timothy Bettington sold 4,350 shares of Elanco Animal Health stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $23.00, for a total transaction of $100,050.00. Following the sale, the insider owned 138,911 shares in the company, valued at approximately $3,194,953. This trade represents a 3.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elanco Animal Health Price Performance

NYSE ELAN traded down $0.05 on Monday, reaching $23.50. The company’s stock had a trading volume of 2,900,342 shares, compared to its average volume of 5,612,071. Elanco Animal Health Incorporated has a 52 week low of $19.40 and a 52 week high of $27.98. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The firm has a market cap of $11.74 billion, a PE ratio of -57.31, a price-to-earnings-growth ratio of 1.68 and a beta of 1.70. The business has a 50-day moving average price of $23.22 and a 200 day moving average price of $23.58.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Sell-side analysts expect that Elanco Animal Health Incorporated will post 1.13 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. UBS Group increased their target price on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. Finally, Morgan Stanley lifted their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.91.

Institutional Trading of Elanco Animal Health

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Elanco Animal Health during the second quarter worth approximately $1,202,198,000. Primecap Management Co. CA acquired a new position in shares of Elanco Animal Health in the 2nd quarter worth approximately $1,118,402,000. State Street Corp boosted its holdings in shares of Elanco Animal Health by 4.7% in the 2nd quarter. State Street Corp now owns 16,063,046 shares of the company’s stock worth $395,312,000 after acquiring an additional 726,567 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Elanco Animal Health in the 2nd quarter worth approximately $205,636,000. Finally, Sei Investments Co. grew its position in Elanco Animal Health by 737.5% during the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock worth $135,214,000 after acquiring an additional 4,975,721 shares during the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.